Holen Sie sich die Stockscreener-App
0.84
4.55%
-0.04
Handel nachbörslich:
.86
0.02
+2.38%
Schlusskurs vom Vortag:
$0.88
Offen:
$0.9
24-Stunden-Volumen:
159.88K
Relative Volume:
0.35
Marktkapitalisierung:
$56.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-0.972
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-4.55%
1M Leistung:
+4.69%
6M Leistung:
-66.93%
1J Leistung:
-41.67%
1-Tages-Spanne:
$0.836
$0.9049
1-Wochen-Bereich:
$0.836
$0.95
52-Wochen-Spanne:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Vergleichen Sie IFRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.84 | 59.62M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
Sector ETF performance correlation with InflaRx N.V.Free Opportunity Map for Daily Stock Trading - Newser
Understanding InflaRx N.V.’s price movementPrice Action Based Buy Zone Forecast - Newser
Is it time to cut losses on InflaRx N.V.Secure Entry Point Finder with Analysis - Newser
Why InflaRx N.V. stock attracts strong analyst attentionDownside Control Plan With Support Analysis - Newser
Is InflaRx N.V. Stock a Good Fit for Conservative InvestorsEarly Entry Ideas with Momentum Potential - Newser
Sentiment analysis tools applied to InflaRx N.V.Real Time Alert System for Market Moves - Newser
How high can InflaRx N.V. stock goVolume Confirmed Setup with Entry Confidence - Newser
Tools to assess InflaRx N.V.’s risk profileFree Profit Target Stock Opportunity Monitor - Newser
What to do if you’re stuck in InflaRx N.V.Free Swing Trading Plan With Smart Signals - Newser
Applying chart zones and confluence areas to InflaRx N.V.Real Time Screener for Growth Trades - Newser
What MACD signals say about InflaRx N.V.Free Beginner Friendly Stock Selection Guide - Newser
What are analysts’ price targets for InflaRx N.V. in the next 12 monthsUnlock powerful portfolio management tools - Jammu Links News
How does InflaRx N.V. compare to its industry peersMaximize portfolio returns with smart trading - Jammu Links News
What drives InflaRx N.V. stock priceFree Stock Market Return Analysis - Jammu Links News
Should I hold or sell InflaRx N.V. stock in 2025Invest smarter with expert trading signals - Jammu Links News
What is InflaRx N.V. company’s growth strategyTransform your portfolio with high-yield stocks - Jammu Links News
What are the latest earnings results for InflaRx N.V.Consistent high-performance stocks - Jammu Links News
Key resistance and support levels for InflaRx N.V.Free Fundamental Winners With Safe Entry Plan - Newser
Applying Elliott Wave Theory to InflaRx N.V.Free Scalable Portfolio Growth Suggestions - Newser
How does InflaRx N.V. generate profit in a changing economyConsistently superior profits - Jammu Links News
How many analysts rate InflaRx N.V. as a “Buy”Exceptional ROI - Jammu Links News
When is InflaRx N.V. stock expected to show significant growthMaximize portfolio returns with smart trading - Jammu Links News
InflaRx (IFRX) to Release Earnings on Thursday - Defense World
How volatile is InflaRx N.V. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Sentiment Turns Positive on InflaRx N.V. — Reversal AheadLong Hold Safe Return Strategy Reviewed - metal.it
InflaRx N.V. stock momentum explainedFree Low Risk Buy Zone Opportunity Watch - Newser
Does InflaRx N.V. stock perform well during market downturnsReal Time Tracker With High Returns - Jammu Links News
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule - MSN
InflaRx (NASDAQ:IFRX) Trading 2.8% Higher – What’s Next? - Defense World
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 - GlobeNewswire
InflaRx Q2 Earnings Coming August 7: Anti-Inflammatory Drug Developer's Latest Financial Picture - Stock Titan
Top Risks to Consider Before Buying InflaRx N.V. Stock7-Day Equity Return Range Forecast Model - Newser
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):